IP Verse

Combinations Of Akt Inhibitor Compounds And Abiraterone, And Methods Of Use - EP2694072

The patent EP2694072 was granted to Genentech on Aug 7, 2024. The application was originally filed on Mar 30, 2012 under application number EP12764765A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2694072

GENENTECH
Application Number
EP12764765A
Filing Date
Mar 30, 2012
Status
Patent Maintained As Amended
Jul 5, 2024
Grant Date
Aug 7, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 29, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5604213
DESCRIPTIONUS5618807
OPPOSITIONUS2008051399
OPPOSITIONUS2009013795
OPPOSITIONUS2010069357
SEARCHUS2008051399

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "Assessment report for zytiga (abiraterone)", European Medicines Agency, (20110721), pages 1 - 78, XP055205316
OPPOSITION- Copy of declaration of Deepak Sampath
OPPOSITION- Debashis Sarker et al., "Clin Cancer Res", Targeting the Pl3K/AKT Pathway for the Treatment of Prostate Cancer, (20090000), vol. 15, no. 15, pages 4799 - 4805
OPPOSITION- "Study of lpatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy", clinicaltrial.gov NCT01485861, (20120302), URL: www.clinicaltrial.gov, XP055515649
OPPOSITION- BRETT S. CARVER et al., "Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer", Cancer cell, (20110000), vol. 19, no. 5, pages 575 - 586, XP055039150
OPPOSITION- Li Xin et al., "Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor", PNAS, (20060000), vol. 103, no. 20, pages 7789 - 7794, XP055515603
OPPOSITION- Hui-Kuan Lin et al., "Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers) also suggests combinations of AKT inhibitors and AR blockers", The Journal of Biological Chemistry, (20031219), vol. 278, no. 51, pages 50902 - 50907, XP055515579
OPPOSITION- Debashis Sarker et al., "Clin Cancer Res", Targeting the Pl3K/AKT Pathway for the Treatment of Prostate Cancer, (20090000), vol. 15, no. 15, pages 4799 - 4805, XP055515608
SEARCH- BRETT S. CARVER ET AL, "Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer", CANCER CELL, (20110517), vol. 19, no. 5, doi:10.1016/j.ccr.2011.04.008, ISSN 1535-6108, pages 575 - 586, XP055039150 [YP] 1-15 * page 583 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents